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Abstract
Objective Pelvic lymph node dissection (PLND) is the
gold standard procedure for nodal staging in prostate can-
cer (PC) but less commonly used due to its invasiveness.
More commonly computerized tomography (CT) and
magnetic resonance imaging (MRI) are used although these
have limited sensitivities and specificities. The aim of this
study was to find out the correlation between higher scrotal
uptake ratio (SUR) of 99mTc-methylene diphosphonate
(MDP) on bone scan and pelvic node metastasis in patients
with PC at high risk for nodal metastasis.
Methods This was a retrospective study which included
68 biopsy proven newly diagnosed PC patients who had
bone scan from January 2008 till January 2012. MRI of the
pelvis, prostate specific antigen (PSA) and Gleason’s score
were available in all patients. Whole body bone scan was
performed in all patients and SUR was calculated by
dividing mean counts over scrotum and soft tissue over
lateral aspect of right thigh. PLND was carried out within
2–3 weeks of MRI study in these patients.
Results Mean age of studied males was 71 ± 07 years
with a mean PSA level of 65 ± 162 ng/ml. Prostate biopsy
revealed adenocarcinoma in all patients with mean Glea-
son’s score 7 ± 1. Mean SUR was 2.786 ± 0.496. MRI was
positive for pelvic lymphadenopathy in 32/68 (47 %). PLND
revealed evidence of nodal metastasis in 16/68 (24 %)
patients. Receiver operating characteristic analysis revealed
good diagnostic strength of SUR for nodal metastasis with a
cut off value of[2.99 with an area under curve (AUC) 0.708
(95 % CI 0.533–0.847, p value\0.05) and a mean sensitivity
of 68.75 % and mean specificity of 80 %. Diagnostic
strength of MRI for nodal metastasis was found to be low
(AUC 0.566, 95 % CI 0.047–0.657, non-significant p value).
No significant correlation was found between SUR and PSA
in nodes positive and nodes negative patients.
Conclusion We conclude that in newly diagnosed PC
patients, higher SUR on bone scan has a high diagnostic
accuracy for pelvic node metastasis. Furthermore, a bone
scan with a SUR \2.99 and negative for bone metastasis
can stratify newly diagnosed PC patients as low risk.
Keywords Carcinoma prostate  Pelvic node metastasis 
Bone scan  Scrotal uptake ratio
Introduction
Prostate cancer (PC) is the most common malignancy and
third leading cause of death in American men [1]. Accurate
detection of lymph node metastasis in PC is an essential
step of approach for treatment and to predict prognosis.
Presence of metastasis in one lymph node changes the
status of PC from a local to a systemic disease with limited
curative options. Bilateral pelvic lymph node dissection
(PLND) in patients with intermediate to high risk for nodal
metastasis is the standard procedure before radical prosta-
tectomy or curative radiotherapy [2, 3]. CT and MRI have
limited sensitivities and specificities due to inability to
identify metastases in normal-sized nodes and nodal
enlargement secondary to benign reason [4], respectively.
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MR lymphography using superparamagnetic nanoparticles
has reported high accuracy for small nodal deposits [5], but
the technique is not widely available and expensive too.
Bone scan is an important tool for the detection of
skeletal metastasis in PC patients with a prostate specific
antigen (PSA) more than 10 ng/ml [6]. Higher scrotal
uptake of Tc-99m MDP has been reported in patients with
PC as compared to patients who had bone scans either for
some benign or non-prostatic malignant reasons [7].
The objective of this study was to compare the diag-
nostic strength of scrotal uptake ratio of Tc-99m MDP on
bone scan and MRI for nodal metastasis using pelvic nodes
biopsies as gold standard in recently diagnosed patients
with PC at high risk for nodal metastasis.
Materials and method
This was a retrospective study which included 68 PC patients
who underwent PLND because of high risks of having lymph
node involvement out of all 119 pathologically proven PC
patients. These patients had their bone scans done as a part of
staging workup at Nuclear Medicine Section, Department of
Radiology, The Aga Khan University Hospital (AKUH),
Karachi, Pakistan from January 2008 till January 2012. The
study was duly approved by ethical and research committee.
The mean age of patients was 71 ± 07 years with a mean
PSA level of 65 ± 162 ng/ml (range 0.903–2000). Prostate
biopsy revealed adenocarcinoma in all patients with a mean
Gleason’s score 7 ± 1 (Table 1).
MRI was performed in all patients using 1.5 Tesla scanner
(Avanto 76 9 18, Siemens, Germany) and multiplanar and
multisequential images of the abdomen and pelvis were
obtained with and without intravenous contrast administra-
tion (Gadolinium DTPA). T2 weighted (sagittal, coronal,
axial), diffusion weighted (DW) axial and post contrast T1-
fat-saturation (axial, coronal and sagittal) sequences were
acquired. Lymph nodes were reported as malignant if the
short-axis diameter was elongated and [10 mm or was
rounded and[8 mm, according to standard criteria [8].
Bone scan was performed in all patients with 20–25 mCi
(740–925 MBq) of Tc-99m MDP injected intravenously and
after 3 h whole body images were acquired under double
head gamma camera fitted with low energy high resolution
collimator (Ecam, Siemens, Germany). For quantitative
analysis, square-shaped regions of interest (ROIs) of 144
pixels were placed centrally on the scrotum and then on the
right thigh laterally (for correction of background) to avoid
superimposition of major vessels and bones [7]. Scrotal
uptake ratio (SUR), ratio of mean counts of the scrotal and
femoral soft tissue ROIs (St/Bg), was calculated in each
individual (Fig. 1). PLND was carried out within 2–3 weeks
of bone scan and MRI study in patients with PSA[10 ng/ml
and GS [6 as these patients are supposed to have higher
probability for nodal metastasis. PSA and Gleason’s score
were also available in all patients.
Data were analyzed using the commercially available
statistical software package MedCalc version 11.3.10 and
Table 1 Patients’
demographics
PSA prostatic specific antigen,
SD standard deviation, MRI
magnetic resonance imaging,
PLND pelvic lymph node
dissection, HP histopathology
* p \ 0.05
Variables Total population (68) t test p value
Age (mean ± SD) years 71 ± 07 83.581 \0.0001*
PSA (mean ± SD) ng/ml 65 ± 162 (0.903–2000) 3.306 0.0015*
Gleason Score (GS) (mean ± SD) 7 ± 1 57.311 \0.0001*
Scrotal uptake on bone scan (mean ± SD) 2.786 ± 0.496 45.487 \0.0001*
Lymphadenopathy on MRI 32/68 (47 %) 173.186 \0.0001*
HP positive in PLND 16/68 (24 %) 88.345 \0.0001*
Fig. 1 Whole body bone scan (anterior view) with ROIs over
scrotum and lateral aspect of right thigh for estimation of scrotal
uptake ratio
Ann Nucl Med (2012) 26:676–680 677
123
SPSS software version 10. For univariate analysis, Chi-
square test was performed for discrete and Student’s t test
was used for continuous variables. Receiver operating
characteristics curves (ROC) were plotted for diagnostic
strength of SUR and MRI against histopathology. Corre-
lation of SUR against PSA was calculated by regression
analysis. All p values \0.05 were selected as significant.
Results
Mean SUR was 2.86 ± 0.459. MRI was positive for pelvic
lymphadenopathy in 32/68 (47 %). PLND revealed evi-
dence of nodal metastasis in 16/68 (24 %) patients
(Table 1). Based on histopathology results of PLND, the
cohort was divided into two groups with (16/68) or without
nodal metastasis (52/68). The mean SUR in patients with
nodal metastasis was significantly higher than patients with
no nodal metastasis (Table 2).
Receiver operating characteristic analysis for measuring
diagnostic strength of SUR for nodal metastasis on histo-
pathology revealed a cut off value of more than 2.99 with
an area under curve (AUC) 0.708 (95 % CI 0.533–0.847,
p value\0.05; Table 3) and a mean sensitivity of 68.75 %
(range 41.4–81.9) and mean specificity of 80 % (range
56.3–94.1) (Fig. 2). Figure 3 depicts the diagnostic
strength of MRI for nodal metastasis with AUC of 0.566
(95 % CI 0.047–0.657, non-significant p value; Table 3)
with a mean sensitivity of 28.3 % (range 16.0–43.5) and
mean specificity of 84.9 % (range 74.6–92.2). Scatter plot
comparing the SUR and PSA in nodes positive and nodes
negative patients showed no significant correlation with r:
0.227 and 0.104, respectively (non-significant p values)
(Fig. 4a, b).
Table 2 Comparison of scrotal uptake ratio with nodal status on histopathology
Total PLND (68) HP positive (16) HP negative (52) p value
SUR (mean ± SD) 3.019 ± 0.409 2.55 ± 0.58 0.0037*
PLND pelvic lymph node dissection, HP histopathology, SUR scrotal uptake ratio, SD standard deviation
* p \ 0.05
Table 3 Receiver operating characteristics curve analysis
AUC Standard error 95 % CI Z statistics p value
SUR versus HP 0.708 0.089 0.533–0.847 2.334 0.0196*
MRI versus HP 0.566 0.0545 0.047–0.657 2.983 0.0842
AUC area under curve, CI confidence interval, SUR scrotal uptake ratio, HP Histopathology, MRI magnetic resonance imaging
* p value \0.05
Fig. 2 Receiver operating characteristic analysis of scrotal uptake
ratio with histopathology
Fig. 3 Receiver operating characteristic analysis of MRI with
histopathology
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Discussion
In PC, precise determination of nodal involvement is very
important as a well localized disease without nodal
involvement has the options of radical prostatectomy,
watchful waiting, and radiotherapy. Pelvic lymph node
dissection is the standard procedure for precise local
staging but it is an invasive procedure, carries surgery-
related morbidities and increases treatment cost as well.
For these reasons, cross-sectional imaging like CT and
MRI being non-invasive modalities are primarily used for
local staging in PC.
Bone scan is the most common functional imaging
which is used for the assessment of bony metastasis in
patients with PC. Abnormal soft tissue tracer uptake is not
an uncommon finding on bone scan [9]. Higher scrotal
uptake of Tc-99m MDP on a bone scan in patients with PC
has been mentioned in the literature [7]. The possible
mechanisms for this phenomenon may be either vascular
thromboembolism (VTE) due to activation of coagulation
system [10, 11] or lymphedema secondary to lymphangitis
[12] as prostate and scrotum have common lymphatic
drainage pathway [13]. In this study, we have correlated
SUR on bone scan with nodal metastasis found on PLND
biopsies and lymphadenopathy reported on MRI examin-
ations. Our result showed that a SUR [2.99 has a good
diagnostic accuracy for nodal metastasis seen on pelvic
node biopsy. The mean sensitivity of 68.75 % for a SUR
[2.99 indicates a chance of missing the nodal metastasis in
about 31 % (false negative), but high mean specificity
ensures its ability to truly diagnose the nodal metastasis.
We do not have a precise justification for this phenomenon
and assume that lymphangitis due to tumor invasion of
regional lymphatic might be the reason as reported in the
literature [12, 13]. However, further studies are required for
precise evaluation of this important phenomenon. There-
fore, patients whom bone scans reveal a SUR [2.99 must
be considered as high risk for nodal metastasis and PLND
must be considered for precise local staging of PC. Fur-
thermore, in a newly diagnosed PC patient, a negative bone
scan for bone metastasis with a SUR\2.99 may be used as
a tool for selecting patients with localized disease (low risk
group) with expected better outcome.
MRI revealed a weak diagnostic strength (non-signifi-
cant p value) for nodal metastasis found on PLND and this
is due to its inability to identify metastasis in normal-sized
nodes and nodal enlargement secondary to benign reason
[4], respectively. These values are significantly lower than
some reported values [8] and the sentinel reason may be the
use of 3D T1 weighted image sequences which was not
used this study. However, MR lymphography using su-
perparamagnetic nanoparticles has been reported to have
higher sensitivity than conventional MRI (90.5 vs. 35.4 %,
p \ 0.001) [5].
In our study, SUR had no significant correlation with
PSA. According to various studies [14, 15] incidence of
nodal metastasis with a pretreatment PSA \10 ng/ml and
GS B6 is very rare. However, in this study, the mean PSA
was 56 ± 198 ng/ml with a mean GS 7 ± 1 and theoreti-
cally we must have had a significant correlation. The
absence of this correlation indicates that lymphedema may
not be the only mechanism for higher SUR. The other
possible explanation might be an aggressive nature of PC
in Asian population preferentially with an early hematog-
enous spread than nodal metastasis resulting in higher
incidence of bone metastasis even at low PSA level and GS
as reported by our group [16]. Another plausible reason
might be small sample size or sampling error, which is a
limitation of this study. A well-designed study to evaluate
this aspect of the SUR is really warranted.
Fig. 4 a Scatter plot of scrotal uptake ratio on bone scan against
prostatic specific antigen in patients with positive pelvic lymph nodes.
b Scatter plot of scrotal uptake ratio on bone scan against prostatic
specific antigen in patients with negative pelvic lymph nodes
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To the best of our understanding, this is the first study
which correlated SUR on bone scan with nodal metastasis
on PLND biopsies and found a good diagnostic accuracy of
higher SUR ([2.99) for nodal metastasis in newly diag-
nosed PC. Limitations of this study are its retrospective
design, lower number of patients with PLND and lack of
understanding about the precise mechanism of this finding.
We conclude that in newly diagnosed PC higher SUR on
bone scan has a high diagnostic accuracy for nodal
metastasis seen on PLND. Furthermore, a bone scan with a
SUR \2.99 and negative for bone metastasis can stratify
newly diagnosed PC patients as low risk.
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